US117097A
(en)
*
|
|
1871-07-18 |
|
Improvement in brick-machines |
US15133A
(en)
*
|
|
1856-06-17 |
|
Machine fob paring |
SE370449B
(da)
|
1970-08-29 |
1974-10-14 |
Philips Nv |
|
JPS5334319B2
(da)
|
1971-12-28 |
1978-09-20 |
|
|
JPS5717624B2
(da)
|
1974-04-17 |
1982-04-12 |
|
|
JPS5484060A
(en)
|
1977-12-12 |
1979-07-04 |
Kyushu Sekisui Kogyo |
Treatment of raw *wakame* by using chlorella extract
|
US4324710A
(en)
|
1980-10-02 |
1982-04-13 |
The Firestone Tire & Rubber Company |
Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
JPH0234615Y2
(da)
|
1986-08-08 |
1990-09-18 |
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
FR2628833B1
(fr)
|
1988-03-18 |
1993-06-25 |
Pont Sur Sambre Ateliers Mecan |
Dispositif assurant le deconfinement d'une charge militaire contenant un explosif
|
US5126250A
(en)
*
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
NZ230786A
(en)
|
1988-09-28 |
1991-11-26 |
Lilly Co Eli |
A method of reducing the heterogeneity of secreted monoclonal antibodies
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
TW205553B
(da)
|
1991-04-25 |
1993-05-11 |
Chugai Pharmaceutical Co Ltd |
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
US5468634A
(en)
|
1991-06-24 |
1995-11-21 |
The University Of North Carolina At Chapel Hill |
Axl oncogene
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
BR9204244A
(pt)
|
1992-10-26 |
1994-05-03 |
Cofap |
Ferro fundido cinzento
|
JP3095175B2
(ja)
|
1992-11-13 |
2000-10-03 |
アイデック ファーマシューティカルズ コーポレイション |
B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
|
AU689090B2
(en)
|
1992-12-01 |
1998-03-26 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
US5888510A
(en)
|
1993-07-21 |
1999-03-30 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
DE122009000068I2
(de)
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
AU700819B2
(en)
|
1994-10-07 |
1999-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
|
CZ296979B6
(cs)
|
1994-10-21 |
2006-08-16 |
Chugai Seiyaku Kabushiki Kaisha |
Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5876950A
(en)
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
CN1097438C
(zh)
|
1995-02-28 |
2003-01-01 |
普罗格特-甘布尔公司 |
微生物稳定的非充气饮料产品的制备
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
AU690474B2
(en)
|
1995-09-11 |
1998-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody againts alpha-chain of human interleukin 5 receptor
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US20020147326A1
(en)
|
1996-06-14 |
2002-10-10 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
WO1998003546A1
(en)
|
1996-07-19 |
1998-01-29 |
Amgen Inc. |
Analogs of cationic proteins
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
DK2011514T3
(da)
|
1997-03-21 |
2012-03-26 |
Chugai Pharmaceutical Co Ltd |
Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
KR20080027967A
(ko)
|
1997-08-15 |
2008-03-28 |
츄가이 세이야꾸 가부시키가이샤 |
항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
|
CN1277632A
(zh)
|
1997-10-03 |
2000-12-20 |
中外制药株式会社 |
天然人源化抗体
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
IL136544A0
(en)
|
1997-12-05 |
2001-06-14 |
Scripps Research Inst |
Humanization of murine antibody
|
PT1074268E
(pt)
|
1998-03-17 |
2008-02-28 |
Chugai Pharmaceutical Co Ltd |
Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
HUP0101160A2
(hu)
|
1998-04-03 |
2001-08-28 |
Chugai Seiyaku Kabushiki Kaisha |
Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
EP1135415B1
(en)
|
1998-12-01 |
2010-08-11 |
Facet Biotech Corporation |
Humanized antibodies to gamma-interferon
|
CN1202128C
(zh)
|
1998-12-08 |
2005-05-18 |
拜奥威神有限公司 |
修饰蛋白的免疫原性
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
DK2270150T4
(da)
|
1999-04-09 |
2019-08-26 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
ATE455852T1
(de)
|
1999-06-02 |
2010-02-15 |
Chugai Pharmaceutical Co Ltd |
Neues hämopoietin rezeptorprotein nr10
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
MXPA02003456A
(es)
|
1999-10-04 |
2002-10-23 |
Medicago Inc |
Metodo para regular la transcripcion de genes foraneos.
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
CA2395660A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
US20020164668A1
(en)
|
2000-04-03 |
2002-11-07 |
Durham L. Kathryn |
Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
CA2406650C
(en)
|
2000-05-03 |
2009-07-21 |
Mbt Munich Biotechnology Ag |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
PL218428B1
(pl)
|
2000-10-06 |
2014-12-31 |
Kyowa Hakko Kogyo Kk |
Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
|
JP4776145B2
(ja)
|
2000-10-25 |
2011-09-21 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する乾癬の予防又は治療剤
|
JP4889187B2
(ja)
|
2000-10-27 |
2012-03-07 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
CA2440221C
(en)
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
ATE471344T1
(de)
*
|
2001-04-13 |
2010-07-15 |
Biogen Idec Inc |
Antikörper gegen vla-1
|
KR20080077295A
(ko)
|
2001-06-22 |
2008-08-21 |
츄가이 세이야꾸 가부시키가이샤 |
항글리피칸 3항체를 포함하는 세포증식 억제제
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
KR20100018071A
(ko)
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
ES2392073T3
(es)
|
2001-11-08 |
2012-12-04 |
Abbott Biotherapeutics Corp. |
Formulación farmacéutica líquida estable de anticuerpos IGG
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP1464702A4
(en)
|
2001-12-28 |
2005-09-21 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PROTEIN STABILIZATION
|
DK1476541T3
(da)
|
2002-01-18 |
2008-11-03 |
Zymogenetics Inc |
Cytokin (zcytor17-ligand)
|
DK1576112T3
(da)
|
2002-01-18 |
2012-06-25 |
Zymogenetics Inc |
Cytokin-receptor zcytor17-multimerer
|
MXPA04007583A
(es)
|
2002-02-11 |
2005-04-25 |
Genentech Inc |
Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
EP1495055B1
(en)
|
2002-04-18 |
2013-08-14 |
Genencor International, Inc. |
Production of functional antibodies in filamentous fungi
|
EP1510943A4
(en)
|
2002-05-31 |
2007-05-09 |
Celestar Lexico Sciences Inc |
INTERACTION PREDICTION DEVICE
|
JP2004086862A
(ja)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
WO2003105757A2
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
EP1382969A1
(en)
|
2002-07-17 |
2004-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Diagnosis and prevention of cancer cell invasion
|
TW200407335A
(en)
|
2002-07-22 |
2004-05-16 |
Chugai Pharmaceutical Co Ltd |
Non-neutralizing antibody to inhibit the inactivation of activated protein C
|
WO2004016740A2
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
GB0224082D0
(en)
|
2002-10-16 |
2002-11-27 |
Celltech R&D Ltd |
Biological products
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
ATE553128T1
(de)
*
|
2002-12-24 |
2012-04-15 |
Rinat Neuroscience Corp |
Anti-ngf-antikörper und verfahren zu ihrer verwendung
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1608684A2
(en)
|
2003-02-07 |
2005-12-28 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
US20040223970A1
(en)
|
2003-02-28 |
2004-11-11 |
Daniel Afar |
Antibodies against SLC15A2 and uses thereof
|
JP2006521387A
(ja)
|
2003-03-04 |
2006-09-21 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
DE602004028347D1
(de)
|
2003-03-24 |
2010-09-09 |
Zymogenetics Inc |
Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
|
JP2004321100A
(ja)
|
2003-04-25 |
2004-11-18 |
Rikogaku Shinkokai |
IgGのFc領域を含むタンパク質の変異体
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP2395016A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
JP2007536896A
(ja)
|
2003-06-05 |
2007-12-20 |
ジェネンテック・インコーポレーテッド |
Blysアンタゴニストとその用途
|
WO2004113387A2
(en)
*
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
CA2531482A1
(en)
|
2003-06-30 |
2005-01-20 |
Centocor, Inc. |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
JP2005101105A
(ja)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
位置決め装置、露光装置、デバイス製造方法
|
US20060134105A1
(en)
*
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
EP1688439A4
(en)
|
2003-10-08 |
2007-12-19 |
Kyowa Hakko Kogyo Kk |
HYBRID PROTEIN COMPOSITION
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
JPWO2005035754A1
(ja)
|
2003-10-14 |
2006-12-21 |
中外製薬株式会社 |
機能蛋白質を代替する二種特異性抗体
|
CA2545539A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
PL1690550T3
(pl)
|
2003-10-17 |
2013-01-31 |
Chugai Pharmaceutical Co Ltd |
Środek do leczenia międzybłoniaka
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
PT1691837E
(pt)
|
2003-12-10 |
2012-08-27 |
Medarex Inc |
Anticorpos ip-10 e suas utilizações
|
EP2418220B1
(en)
|
2003-12-10 |
2017-08-02 |
E. R. Squibb & Sons, L.L.C. |
Interferon alpha antibodies and their uses
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
EP1697748A4
(en)
|
2003-12-22 |
2007-07-04 |
Centocor Inc |
METHODS FOR GENERATING MULTIMEDIA MOLECULES
|
US8568725B2
(en)
|
2003-12-25 |
2013-10-29 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating transplant rejection with an anti-CD40 antibody
|
EP1699822B1
(en)
*
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
DE602005020743D1
(de)
|
2004-02-11 |
2010-06-02 |
Warner Lambert Co |
Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
EP3736295A1
(en)
|
2004-03-24 |
2020-11-11 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleukin-6 receptor
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
JP2008504289A
(ja)
|
2004-06-25 |
2008-02-14 |
メディミューン,インコーポレーテッド |
部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
|
US9012369B2
(en)
|
2004-07-06 |
2015-04-21 |
Pfizer Inc. |
Look-through mutagenesis for developing altered polypeptides with enhanced properties
|
CN103351434B
(zh)
|
2004-07-15 |
2015-09-30 |
赞科股份有限公司 |
优化的Fc变体
|
WO2006031370A2
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2577082A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
CA2579142A1
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
AU2005284006A1
(en)
|
2004-09-14 |
2006-03-23 |
Health Protection Agency |
Vaccine
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
CA2580981C
(en)
|
2004-09-22 |
2013-10-22 |
Kirin Beer Kabushiki Kaisha |
Stabilized human igg4 antibodies
|
JP4948413B2
(ja)
|
2004-09-23 |
2012-06-06 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体および結合体
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
EP1805320B1
(en)
*
|
2004-10-22 |
2014-09-03 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
AU2005302453A1
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Llc |
Methods of preventing and treating RSV infections and related conditions
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
AU2005335714B2
(en)
*
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CA2586803C
(en)
|
2004-12-14 |
2012-12-11 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
US8728828B2
(en)
|
2004-12-22 |
2014-05-20 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
AU2005321974B2
(en)
|
2004-12-27 |
2011-11-17 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally deliverable and anti-toxin antibodies and methods for making and using them
|
ES2557325T5
(es)
|
2004-12-28 |
2023-11-15 |
Innate Pharma Sa |
Anticuerpos monoclonales contra NKG2A
|
PT1699826E
(pt)
|
2005-01-05 |
2009-06-17 |
F Star Biotech Forsch & Entw |
Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
|
US20060275282A1
(en)
*
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
WO2006088855A1
(en)
|
2005-02-14 |
2006-08-24 |
Zymogenetics, Inc. |
Methods of treating skin disorders using an il-31ra antagonist
|
US7700099B2
(en)
*
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
DK2824183T3
(da)
|
2005-04-08 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af bispecifikke antistoffer
|
US7737115B2
(en)
|
2005-04-15 |
2010-06-15 |
Genetech, Inc. |
HGF beta chain variants
|
US8008443B2
(en)
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
WO2006132341A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2部位特異的変異体
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
BRPI0612814A2
(pt)
|
2005-07-11 |
2017-06-20 |
Macrogenics Inc |
anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente
|
PT2573114T
(pt)
*
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
CN103450359B
(zh)
|
2005-08-19 |
2018-07-24 |
惠氏有限责任公司 |
抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
|
EP1789435B1
(en)
|
2005-09-12 |
2010-02-24 |
Industry Foundation of Chonnam National University |
A method for production of mature natural killer cell
|
JP2009510102A
(ja)
*
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
免疫調節組成物およびその使用
|
BRPI0617378B8
(pt)
|
2005-10-14 |
2022-09-20 |
Chugai Pharmaceutical Co Ltd |
Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
JP2009528264A
(ja)
|
2006-01-10 |
2009-08-06 |
ザイモジェネティクス,インコーポレイティド |
Il−31アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
|
NZ599035A
(en)
|
2006-01-12 |
2013-12-20 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
AU2007208678B2
(en)
|
2006-01-27 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for diseases involving choroidal neovascularization
|
US8048421B2
(en)
|
2006-03-23 |
2011-11-01 |
Kyowa Hakko Kirin Co., Ltd. |
Agonist antibody to human thrombopoietin receptor
|
PL2004688T5
(pl)
|
2006-03-23 |
2014-09-30 |
Bioarctic Neuroscience Ab |
Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
IN2014DN10515A
(da)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
EP2025346B1
(en)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Muscle regeneration promoter
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
AU2007267213B2
(en)
|
2006-05-25 |
2012-03-29 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
CA2652976C
(en)
|
2006-06-02 |
2015-08-11 |
Regeneron Pharmaceuticals, Inc. |
High affinity antibodies to human il-6 receptor
|
ES2429407T3
(es)
|
2006-06-08 |
2013-11-14 |
Chugai Seiyaku Kabushiki Kaisha |
Agente preventivo o remedio para enfermedades inflamatorias
|
EP2032602B1
(en)
|
2006-06-15 |
2013-03-27 |
The Board of Trustees of the University of Arkansas |
Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CL2008000188A1
(es)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
WO2008090960A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
WO2008100995A1
(en)
|
2007-02-14 |
2008-08-21 |
Vaccinex, Inc. |
Humanized anti-cd100 antibodies
|
RS52345B
(en)
|
2007-02-23 |
2012-12-31 |
Schering Corporation |
ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING
|
EP2138576A4
(en)
|
2007-03-16 |
2011-02-23 |
Kyowa Hakko Kirin Co Ltd |
ANTI-CLAUDIN-4 ANTIBODY
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
GB0708002D0
(en)
|
2007-04-25 |
2007-06-06 |
Univ Sheffield |
Antibodies
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
EP2155790A1
(en)
|
2007-05-31 |
2010-02-24 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
US20100226925A1
(en)
*
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
AR068564A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti- receptor de il-6 (interleuquina 6)
|
CA2700701C
(en)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
WO2009041734A1
(ja)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
PL3059246T3
(pl)
|
2007-09-26 |
2018-11-30 |
Chugai Seiyaku Kabushiki Kaisha |
Zmodyfikowany region stały przeciwciała
|
EP2584043A3
(en)
|
2007-09-28 |
2013-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody having improved kinetics in plasma
|
BR122019021238B8
(pt)
|
2007-10-02 |
2021-07-27 |
Chugai Pharmaceutical Co Ltd |
uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
ES2400107T3
(es)
|
2007-10-22 |
2013-04-05 |
Merck Serono S.A. |
IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado
|
SG188134A1
(en)
|
2007-11-15 |
2013-03-28 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
WO2009072598A1
(ja)
|
2007-12-05 |
2009-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
掻痒症治療剤
|
ES2834741T3
(es)
*
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
BRPI0820452A2
(pt)
|
2007-12-18 |
2015-06-16 |
Bioalliance Cv |
Anticorpos que reconhecendo um epítopo contendo um carboidrato em cd-43 e cea expressos em células cancerosas e métodos de uso dos mesmos.
|
EP4098661A1
(en)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
DK2235064T3
(da)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
Fremgangsmåde til fremstilling af Fc-heterodimeriske molekyler under anvendelse af elektrostatiske styringseffekter
|
EP2250279B1
(en)
|
2008-02-08 |
2016-04-13 |
MedImmune, LLC |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
SG189775A1
(en)
|
2008-04-11 |
2013-05-31 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
TW201503898A
(zh)
|
2008-06-05 |
2015-02-01 |
Chugai Pharmaceutical Co Ltd |
神經浸潤抑制劑
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010043977A2
(en)
|
2008-10-13 |
2010-04-22 |
Institute For Research In Biomedicine |
Dengue virus neutralizing antibodies and uses thereof
|
KR102100066B1
(ko)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
EP2361095B1
(en)
|
2008-11-25 |
2017-12-20 |
AlderBio Holdings LLC |
Antagonists of il-6 to raise albumin and/or lower crp
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
WO2010064090A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Process for the modulation of the antagonistic activity of a monoclonal antibody
|
KR20160062207A
(ko)
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
US20120149875A1
(en)
|
2009-01-12 |
2012-06-14 |
Ge Healthcare Bio-Sciences Ab |
Affinity chromatography matrix
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
CN102459344A
(zh)
|
2009-05-15 |
2012-05-16 |
中外制药株式会社 |
抗axl抗体
|
MY164121A
(en)
|
2009-06-26 |
2017-11-30 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN104506286B
(zh)
|
2009-12-18 |
2018-02-16 |
韩国电子通信研究院 |
用于在无线通信系统中接收帧的方法和设备
|
ES2777901T3
(es)
|
2009-12-25 |
2020-08-06 |
Chugai Pharmaceutical Co Ltd |
Método de modificación de polipéptidos para purificar multímeros polipeptídicos
|
CN103124743A
(zh)
|
2009-12-29 |
2013-05-29 |
新兴产品开发西雅图有限公司 |
Ron结合构建物及其使用方法
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2525822B1
(en)
|
2010-01-20 |
2017-05-10 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
CN102782131B
(zh)
|
2010-03-02 |
2015-08-05 |
协和发酵麒麟株式会社 |
修饰抗体组合物
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN102844332B
(zh)
|
2010-03-11 |
2015-08-19 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
JP5998050B2
(ja)
|
2010-03-31 |
2016-09-28 |
Jsr株式会社 |
アフィニティークロマトグラフィー用充填剤
|
KR101930964B1
(ko)
|
2010-04-20 |
2018-12-19 |
젠맵 에이/에스 |
이종이량체 항체 fc-함유 단백질 및 그의 생산 방법
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
DK3029066T3
(da)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
Antistoffer med modificerede isoelektriske punkter
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
US8580264B2
(en)
|
2010-11-08 |
2013-11-12 |
Genentech, Inc. |
Subcutaneously administered anti-IL-6 receptor antibody
|
RS57038B1
(sr)
|
2010-11-17 |
2018-05-31 |
Chugai Pharmaceutical Co Ltd |
Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi
|
EP4303237A3
(en)
|
2010-11-30 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
CN103328632A
(zh)
|
2010-11-30 |
2013-09-25 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
KR101904232B1
(ko)
|
2010-12-14 |
2018-10-05 |
내셔널 유니버시티 오브 싱가포르 |
뎅기 바이러스 세로타입 1 e 프로틴에 특이적인 인간 단일클론 항체 및 그들의 용도
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
WO2012145238A2
(en)
|
2011-04-20 |
2012-10-26 |
Tolerx, Inc. |
Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
|
JP5729817B2
(ja)
|
2011-06-29 |
2015-06-03 |
日本電信電話株式会社 |
動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、動画像符号化プログラム及び動画像復号プログラム
|
TW201726745A
(zh)
|
2011-09-30 |
2017-08-01 |
中外製藥股份有限公司 |
促進抗原消失的抗原結合分子
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
CN104114579B
(zh)
|
2011-10-27 |
2020-01-24 |
健玛保 |
异二聚体蛋白的生成
|
ES2899956T3
(es)
|
2011-11-04 |
2022-03-15 |
Zymeworks Inc |
Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
WO2013089647A1
(en)
|
2011-12-16 |
2013-06-20 |
Agency For Science, Technology And Research |
Binding molecules against dengue virus and uses thereof
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2825559B1
(en)
|
2012-03-13 |
2019-02-27 |
Novimmune SA |
Readily isolated bispecific antibodies with native immunoglobulin format
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
BR112014024612A2
(pt)
|
2012-04-02 |
2021-06-08 |
Univ North Carolina Chapel Hill |
ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
US9556254B2
(en)
|
2012-05-14 |
2017-01-31 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Cross-reactive antibodies against dengue virus and uses thereof
|
US20140154270A1
(en)
|
2012-05-21 |
2014-06-05 |
Chen Wang |
Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
EP3892638A1
(en)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
AU2013299986B2
(en)
|
2012-08-07 |
2018-05-17 |
Massachusetts Institute Of Technology |
Anti-dengue virus antibodies and uses thereof
|
EA028244B1
(ru)
|
2012-08-13 |
2017-10-31 |
Ридженерон Фармасьютикалз, Инк. |
АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
|
EP2894171A4
(en)
|
2012-09-10 |
2016-05-25 |
Kaneka Corp |
ADSORPTION
|
WO2014054804A1
(ja)
|
2012-10-05 |
2014-04-10 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
EP2914634B1
(en)
|
2012-11-02 |
2017-12-06 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
CN105143257B
(zh)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
Fc变体
|
US20160031985A1
(en)
|
2013-03-15 |
2016-02-04 |
Katherine S. Bowdish |
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
|
SG10201803449VA
(en)
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
BR112016009919A2
(pt)
|
2013-11-04 |
2017-12-05 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
|
CA3212977A1
(en)
|
2014-02-11 |
2015-08-20 |
Visterra, Inc. |
Antibody molecules to dengue virus and uses thereof
|
EP3104888A4
(en)
|
2014-02-11 |
2017-08-09 |
Massachusetts Institute Of Technology |
Novel full spectrum anti-dengue antibody
|
GB201413086D0
(en)
|
2014-07-23 |
2014-09-03 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
JP6630036B2
(ja)
|
2014-09-30 |
2020-01-15 |
Jsr株式会社 |
標的物の精製方法、及び、ミックスモード用担体
|
CR20170326A
(es)
|
2014-12-19 |
2017-08-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
WO2016136933A1
(ja)
|
2015-02-27 |
2016-09-01 |
中外製薬株式会社 |
Il-6関連疾患治療用組成物
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|